中国医药
中國醫藥
중국의약
China Medicine
2015年
12期
1764-1766
,共3页
脑梗死%依达拉奉%血栓通%神经功能
腦梗死%依達拉奉%血栓通%神經功能
뇌경사%의체랍봉%혈전통%신경공능
Cerebral infarction%Edaravone%Xueshuantong%Neurological function
目的 分析依达拉奉联合血栓通在脑梗死患者治疗中的应用及对神经功能的影响.方法 选择2014年1月至2015年1月江苏省无锡市人民医院收治的100例脑梗死患者,按照入院顺序将患者分为观察组(50例)和对照组(50例).对照组采用血栓通治疗,0.45 g加入250 ml 0.9％氯化钠注射液中静脉滴注,1次/d,连续治疗2周.观察组在对照组的基础上给予依达拉奉治疗,30 mg加入100 ml 0.9％氯化钠注射液中,与加有血栓通的0.9％氯化钠注射液一起进行静脉滴注,1次/d,连续治疗2周.比较2组患者的一般临床资料、临床疗效、神经功能缺损量表评分、日常生活能力指数评分.结果 观察组患者治疗后总有效率明显高于对照组,差异有统计学意义[98.0％ (48/50)比82.0％(41/50),P＜0.05].治疗后1周及治疗后2周,观察组患者神经功能缺损量表评分均低于对照组,差异有统计学意义[(16.3±3.2)分比(23.6±4.8)分、(12.1±2.5)分比(17.6±3.2)分,P＜0.05].治疗后1周及治疗后2周,观察组患者的日常生活能力指数评分均高于对照组,差异有统计学意义[(50±13)分比(41±11)分、(67±14)分比(51±11)分,P＜0.05].结论 依达拉奉联合血栓通治疗脑梗死效果良好,能明显提高患者的神经功能以及日常生活能力.
目的 分析依達拉奉聯閤血栓通在腦梗死患者治療中的應用及對神經功能的影響.方法 選擇2014年1月至2015年1月江囌省無錫市人民醫院收治的100例腦梗死患者,按照入院順序將患者分為觀察組(50例)和對照組(50例).對照組採用血栓通治療,0.45 g加入250 ml 0.9％氯化鈉註射液中靜脈滴註,1次/d,連續治療2週.觀察組在對照組的基礎上給予依達拉奉治療,30 mg加入100 ml 0.9％氯化鈉註射液中,與加有血栓通的0.9％氯化鈉註射液一起進行靜脈滴註,1次/d,連續治療2週.比較2組患者的一般臨床資料、臨床療效、神經功能缺損量錶評分、日常生活能力指數評分.結果 觀察組患者治療後總有效率明顯高于對照組,差異有統計學意義[98.0％ (48/50)比82.0％(41/50),P＜0.05].治療後1週及治療後2週,觀察組患者神經功能缺損量錶評分均低于對照組,差異有統計學意義[(16.3±3.2)分比(23.6±4.8)分、(12.1±2.5)分比(17.6±3.2)分,P＜0.05].治療後1週及治療後2週,觀察組患者的日常生活能力指數評分均高于對照組,差異有統計學意義[(50±13)分比(41±11)分、(67±14)分比(51±11)分,P＜0.05].結論 依達拉奉聯閤血栓通治療腦梗死效果良好,能明顯提高患者的神經功能以及日常生活能力.
목적 분석의체랍봉연합혈전통재뇌경사환자치료중적응용급대신경공능적영향.방법 선택2014년1월지2015년1월강소성무석시인민의원수치적100례뇌경사환자,안조입원순서장환자분위관찰조(50례)화대조조(50례).대조조채용혈전통치료,0.45 g가입250 ml 0.9％록화납주사액중정맥적주,1차/d,련속치료2주.관찰조재대조조적기출상급여의체랍봉치료,30 mg가입100 ml 0.9％록화납주사액중,여가유혈전통적0.9％록화납주사액일기진행정맥적주,1차/d,련속치료2주.비교2조환자적일반림상자료、림상료효、신경공능결손량표평분、일상생활능력지수평분.결과 관찰조환자치료후총유효솔명현고우대조조,차이유통계학의의[98.0％ (48/50)비82.0％(41/50),P＜0.05].치료후1주급치료후2주,관찰조환자신경공능결손량표평분균저우대조조,차이유통계학의의[(16.3±3.2)분비(23.6±4.8)분、(12.1±2.5)분비(17.6±3.2)분,P＜0.05].치료후1주급치료후2주,관찰조환자적일상생활능력지수평분균고우대조조,차이유통계학의의[(50±13)분비(41±11)분、(67±14)분비(51±11)분,P＜0.05].결론 의체랍봉연합혈전통치료뇌경사효과량호,능명현제고환자적신경공능이급일상생활능력.
Objective To analyze the application of edaravone combined with Xueshuantong in treating cerebral infarction and it effect on neurological function.Methods Totally 100 patients with cerebral infarction patients from January 2014 to January 2015 were enrolled and sequentially divided into observation group (50 cases) and control group (50 cases).Control group was treated with Xueshuantong (0.45 g added in 250 ml 0.9％ sodium chloride injection, intravenous drip, 1/d);observation group was treated with edaravone on the basis of therapy in control group (30 mg added in 100 ml 0.9％ sodium chloride injection) 1/d.The treatment was lasted for 2 weeks.The general clinical data, clinical efficacy, neurological impairment rating scale, daily living activity index score were compared between the two groups before and after treatment.Results The total effect rate in observation group was significantly higher than that in control group [98.0％(48/50) vs 82.0％ (48/50) , P ＜ 0.05].The nerve impairment scale score was significantly lower, the daily living activity index score was significantly higher in observation group than those in control group 1 week after treatment,[(16.3 ±3.2) scores vs (23.6 ±4.8) scores, (12.1 ±2.5) scores vs (17.6 ±3.2) scores] and 2 weeks after treatment [(50 ± 13) scores vs (41 ± 11) scores, (67 ± 14) scores vs (51 ± 11) scores] (P ＜0.05).Conclusion Edaravone combined with Xueshuantong has good clinical efficacy in treating cerebral infarction, it can significantly improve the neurological function and activity of daily living.
